212 related articles for article (PubMed ID: 36677600)
21. Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-
Ahsan MJ; Gautam K; Ali A; Ali A; Altamimi ASA; Salahuddin ; Alossaimi MA; Lakshmi SVVNSM; Ahsan MF
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836779
[TBL] [Abstract][Full Text] [Related]
22. New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase.
Mahmoud MA; Mohammed AF; Salem OIA; Gomaa HAM; Youssif BGM
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200009. PubMed ID: 35195309
[TBL] [Abstract][Full Text] [Related]
23. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
24. New Pyrimidine-5-Carbonitriles as COX-2 Inhibitors: Design, Synthesis, Anticancer Screening, Molecular Docking, and In Silico ADME Profile Studies.
Al-Ghulikah HA; El-Sebaey SA; Bass AKA; El-Zoghbi MS
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364312
[TBL] [Abstract][Full Text] [Related]
25. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
27. Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: Design, synthesis, in vitro anticancer and in silico ADME study.
Rasal NK; Sonawane RB; Jagtap SV
Bioorg Chem; 2020 Apr; 97():103660. PubMed ID: 32086056
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and in vitro antitumor evaluation of novel pyrazole-benzimidazole derivatives.
Ren B; Liu RC; Ji K; Tang JJ; Gao JM
Bioorg Med Chem Lett; 2021 Jul; 43():128097. PubMed ID: 33979690
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
30. Novel quinazoline-chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies.
Tokalı FS; Şenol H; Yetke Hİ; Hacıosmanoğlu-Aldoğan E
Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300423. PubMed ID: 37736677
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, single crystal and antitumor activities of benzimidazole-quinazoline hybrids.
Sharma A; Luxami V; Paul K
Bioorg Med Chem Lett; 2013 Jun; 23(11):3288-94. PubMed ID: 23611732
[TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents.
Abd El-Karim SS; Anwar MM; Mohamed NA; Nasr T; Elseginy SA
Bioorg Chem; 2015 Dec; 63():1-12. PubMed ID: 26368040
[TBL] [Abstract][Full Text] [Related]
34. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.
Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A
Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910
[TBL] [Abstract][Full Text] [Related]
36. Purine-benzimidazole hybrids: synthesis, single crystal determination and in vitro evaluation of antitumor activities.
Sharma A; Luxami V; Paul K
Eur J Med Chem; 2015 Mar; 93():414-22. PubMed ID: 25728022
[TBL] [Abstract][Full Text] [Related]
37. Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.
Galal SA; Khairat SHM; Ali HI; Shouman SA; Attia YM; Ali MM; Mahmoud AE; Abdel-Halim AH; Fyiad AA; Tabll A; El-Shenawy R; El Abd YS; Ramdan R; El Diwani HI
Eur J Med Chem; 2018 Jan; 144():859-873. PubMed ID: 29316526
[TBL] [Abstract][Full Text] [Related]
38. Preclinical
Racané L; Cindrić M; Zlatar I; Kezele T; Milić A; Brajša K; Hranjec M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):163-174. PubMed ID: 33404264
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
[TBL] [Abstract][Full Text] [Related]
40. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations.
Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R
Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
